133 related articles for article (PubMed ID: 17332643)
21. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
22. Assessment of MYCN amplification in neuroblastoma biopsies by differential polymerase chain reaction.
Boerner S; Squire J; Thorner P; McKenna G; Zielenska M
Pediatr Pathol; 1994; 14(5):823-32. PubMed ID: 7808981
[TBL] [Abstract][Full Text] [Related]
23. Determination of transgene copy number by real-time quantitative PCR.
Shepherd CT; Moran Lauter AN; Scott MP
Methods Mol Biol; 2009; 526():129-34. PubMed ID: 19378009
[TBL] [Abstract][Full Text] [Related]
24. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions.
Ponchel F; Toomes C; Bransfield K; Leong FT; Douglas SH; Field SL; Bell SM; Combaret V; Puisieux A; Mighell AJ; Robinson PA; Inglehearn CF; Isaacs JD; Markham AF
BMC Biotechnol; 2003 Oct; 3():18. PubMed ID: 14552656
[TBL] [Abstract][Full Text] [Related]
25. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
[TBL] [Abstract][Full Text] [Related]
26. Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction.
Gilbert J; Norris MD; Haber M; Kavallaris M; Marshall GM; Stewart BW
Mol Cell Probes; 1993 Jun; 7(3):227-34. PubMed ID: 8366868
[TBL] [Abstract][Full Text] [Related]
27. A large-scale validation of dosage analysis by robust dosage-polymerase chain reaction.
Nguyen VQ; Liu Q; Sommer SS
Anal Biochem; 2007 Dec; 371(1):37-42. PubMed ID: 17910884
[TBL] [Abstract][Full Text] [Related]
28. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma.
Shapiro DN; Valentine MB; Rowe ST; Sinclair AE; Sublett JE; Roberts WM; Look AT
Am J Pathol; 1993 May; 142(5):1339-46. PubMed ID: 7684192
[TBL] [Abstract][Full Text] [Related]
29. Differential polymerase chain reaction with serial dilutions for quantification of MYCN gene amplification in neuroblastoma.
Gallego S; Reventos J; Sanchez de Toledo J; Munell F
Anticancer Res; 1998; 18(2A):1211-5. PubMed ID: 9615790
[TBL] [Abstract][Full Text] [Related]
30. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
Wan TS; Ma ES; Chan GC; Chan LC
Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
[TBL] [Abstract][Full Text] [Related]
31. Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification.
Hes FJ; van der Luijt RB; Janssen AL; Zewald RA; de Jong GJ; Lenders JW; Links TP; Luyten GP; Sijmons RH; Eussen HJ; Halley DJ; Lips CJ; Pearson PL; van den Ouweland AM; Majoor-Krakauer DF
Clin Genet; 2007 Aug; 72(2):122-9. PubMed ID: 17661816
[TBL] [Abstract][Full Text] [Related]
32. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
[TBL] [Abstract][Full Text] [Related]
33. Von Hippel-Lindau syndrome. A pleomorphic condition.
Friedrich CA
Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173
[TBL] [Abstract][Full Text] [Related]
34. [Familial and genetic study in a large Chinese kindred with von Hippel-Lindau disease and gene mutation analysis].
Zhang J; Huang YR; Wang JD; Fan XD
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Feb; 21(1):5-9. PubMed ID: 14767899
[TBL] [Abstract][Full Text] [Related]
35. A method for accurate detection of genomic microdeletions using real-time quantitative PCR.
Weksberg R; Hughes S; Moldovan L; Bassett AS; Chow EW; Squire JA
BMC Genomics; 2005 Dec; 6():180. PubMed ID: 16351727
[TBL] [Abstract][Full Text] [Related]
36. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
37. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
38. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
39. Detection of n-myc gene amplification in neuroblastoma by comparative, in situ,and real-time polymerase chain reaction.
Melegh Z; Bálint I; Tóth E; Csernák E; Szentirmay Z; Nagy K
Pediatr Pathol Mol Med; 2003; 22(3):213-22. PubMed ID: 12746172
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype.
Chen F; Kishida T; Yao M; Hustad T; Glavac D; Dean M; Gnarra JR; Orcutt ML; Duh FM; Glenn G
Hum Mutat; 1995; 5(1):66-75. PubMed ID: 7728151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
